Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.

Decision regret Localized prostate cancer Locally advanced prostate cancer Treatment decision-making Treatment regret

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
13 May 2024
Historique:
received: 22 01 2024
revised: 06 04 2024
accepted: 29 04 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 14 5 2024
Statut: aheadofprint

Résumé

Treatment decision-making (TDM) for patients with localized (LPC) or locally advanced (LAPC) prostate cancer is complex, and post-treatment decision regret (DR) is common. The factors driving TDM or predicting DR remain understudied. Two systematic literature reviews were conducted to explore the factors associated with TDM and DR. Three online databases, select congress proceedings, and gray literature were searched (September 2022). Publications on TDM and DR in LPC/LAPC were prioritized based on the following: 2012 onward, ≥100 patients, journal article, and quantitative data. The Preferred Reporting Items Reviews and Meta-analyses guidelines were followed. Influential factors were those with p < 0.05; for TDM, factors described as "a decision driver", "associated", "influential", or "significant" were also included. The key factors were determined by number of studies, consistency of evidence, and study quality. Seventy-five publications (68 studies) reported TDM. Patient participation in TDM was reported in 34 publications; overall, patients preferred an active/shared role. Of 39 influential TDM factors, age, ethnicity, external factors (physician recommendation most common), and treatment characteristics/toxicity were key. Forty-nine publications reported DR. The proportion of patients experiencing DR varied by treatment type: 7-43% (active surveillance), 12-57% (radical prostatectomy), 1-49% (radiotherapy), 28-49% (androgen-deprivation therapy), and 21-47% (combination therapy). Of 42 significant DR factors, treatment toxicity (sexual/urinary/bowel dysfunction), patient role in TDM, and treatment type were key. The key factors impacting TDM were physician recommendation, age, ethnicity, and treatment characteristics. Treatment toxicity and TDM approach were the key factors influencing DR. To help patients navigate factors influencing TDM and to limit DR, a shared, consensual TDM approach between patients, caregivers, and physicians is needed. We looked at factors influencing treatment decision-making (TDM) and decision regret (DR) in patients with localized or locally advanced prostate cancer. The key factors influencing TDM were doctor's recommendation, patient age/ethnicity, and treatment side effects. A shared, consensual TDM approach between patients and doctors was found to limit DR.

Identifiants

pubmed: 38744587
pii: S2588-9311(24)00106-8
doi: 10.1016/j.euo.2024.04.016
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Benjamin A Gartrell (BA)

Departments of Oncology and Urology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA. Electronic address: bgartrel@montefiore.org.

Angaja Phalguni (A)

Evidence Synthesis, Genesis Research Group, Newcastle upon Tyne, UK.

Paulina Bajko (P)

Evidence Synthesis, Genesis Research Group, Newcastle upon Tyne, UK.

Suneel D Mundle (SD)

Global Medical Affairs, Janssen Research & Development, Raritan, NJ, USA.

Sharon A McCarthy (SA)

Clinical Research Oncology, Janssen Research & Development, Raritan, NJ, USA.

Sabine D Brookman-May (SD)

Clinical Research Oncology, Janssen Research & Development, Spring House, PA, USA; Ludwig-Maximilians-University, München, Germany.

Francesco De Solda (F)

Global Commercial Strategy Organization, Janssen Global Services, Raritan, NJ, USA.

Ruhee Jain (R)

Global Commercial Strategy Organization, Janssen Global Services, Raritan, NJ, USA.

Wellam Yu Ko (W)

University of British Columbia Men's Health Research Program, Vancouver, BC, Canada.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France.

Boris Hadaschik (B)

Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Classifications MeSH